IT1313585B1 - Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. - Google Patents

Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.

Info

Publication number
IT1313585B1
IT1313585B1 IT1999MI001715A ITMI991715A IT1313585B1 IT 1313585 B1 IT1313585 B1 IT 1313585B1 IT 1999MI001715 A IT1999MI001715 A IT 1999MI001715A IT MI991715 A ITMI991715 A IT MI991715A IT 1313585 B1 IT1313585 B1 IT 1313585B1
Authority
IT
Italy
Prior art keywords
nicotino
employees
receptor agonists
maintenance therapy
gabab receptor
Prior art date
Application number
IT1999MI001715A
Other languages
English (en)
Italian (it)
Inventor
Gian Luigi Gessa
Giancarlo Colombo
Luca Pani
Walter Fratta
Original Assignee
Neuroscienze S C A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroscienze S C A R L filed Critical Neuroscienze S C A R L
Publication of ITMI991715A0 publication Critical patent/ITMI991715A0/it
Priority to IT1999MI001715A priority Critical patent/IT1313585B1/it
Priority to DE60017147T priority patent/DE60017147T2/de
Priority to PT00947901T priority patent/PT1202727E/pt
Priority to PCT/EP2000/006120 priority patent/WO2001008675A1/en
Priority to ES00947901T priority patent/ES2235913T3/es
Priority to HK02107911.9A priority patent/HK1046849B/en
Priority to DK00947901T priority patent/DK1202727T3/da
Priority to AT00947901T priority patent/ATE285763T1/de
Priority to CNB00811031XA priority patent/CN1176650C/zh
Priority to CA002379752A priority patent/CA2379752C/en
Priority to EP00947901A priority patent/EP1202727B1/en
Priority to SI200030632T priority patent/SI1202727T1/xx
Priority to AU61534/00A priority patent/AU6153400A/en
Priority to IL14787600A priority patent/IL147876A0/xx
Priority to PL353373A priority patent/PL196334B1/pl
Priority to RU2002105375/15A priority patent/RU2262352C2/ru
Publication of ITMI991715A1 publication Critical patent/ITMI991715A1/it
Priority to IL147876A priority patent/IL147876A/en
Application granted granted Critical
Publication of IT1313585B1 publication Critical patent/IT1313585B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IT1999MI001715A 1999-07-30 1999-07-30 Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. IT1313585B1 (it)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IT1999MI001715A IT1313585B1 (it) 1999-07-30 1999-07-30 Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
CNB00811031XA CN1176650C (zh) 1999-07-30 2000-06-30 巴氯芬在制备治疗烟碱依赖药物中的用途
EP00947901A EP1202727B1 (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependent patients
PCT/EP2000/006120 WO2001008675A1 (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
ES00947901T ES2235913T3 (es) 1999-07-30 2000-06-30 Utilizacion de antiinductores de receptores de gabab y de sus derivados aceptables farmaceuticamente, en la terapia de mantenimiento de la abstinencia de nicotina en pacientes dependientes de la nicotina.
HK02107911.9A HK1046849B (en) 1999-07-30 2000-06-30 Use of GABAB receptor agonist and its pharmaceutically acceptable derivatives in the treatment of nicotine dependence to maintain nicotine withdrawal
DK00947901T DK1202727T3 (da) 1999-07-30 2000-06-30 Anvendelse af agonister af GABAB-receptorer og farmaceutisk acceptable derivater deraf til behandling for at opnå fortsat nikotinafholdenhed hos nikotinafhængige patienter
AT00947901T ATE285763T1 (de) 1999-07-30 2000-06-30 Verwendung von gabab-rezeptor agonisten und deren pharmazeutisch akzeptierbaren derivate bei der therapie zur erhaltung von nikotinabstinenz bei nikotinabhängigen patienten
DE60017147T DE60017147T2 (de) 1999-07-30 2000-06-30 Verwendung von gabab-rezeptor agonisten und deren pharmazeutisch akzeptierbaren derivate bei der therapie zur erhaltung von nikotinabstinenz bei nikotinabhängigen patienten
CA002379752A CA2379752C (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
PT00947901T PT1202727E (pt) 1999-07-30 2000-06-30 Utilizacao de agonistas de receptores gabab e seus derivados farmaceuticamente aceitaveis, na terapia para manter a abstinencia de nicotina em pacientes dependentes de nicotina
SI200030632T SI1202727T1 (enExample) 1999-07-30 2000-06-30
AU61534/00A AU6153400A (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
IL14787600A IL147876A0 (en) 1999-07-30 2000-06-30 Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence-dependent patients
PL353373A PL196334B1 (pl) 1999-07-30 2000-06-30 Zastosowanie agonistów receptorów GABA B i ich farmaceutycznie dopuszczalnych pochodnych w terapii abstynencji nikotynowej u uzależnionych od nikotyny pacjentów
RU2002105375/15A RU2262352C2 (ru) 1999-07-30 2000-06-30 Применение агонистов рецепторов b-типа гамма-аминомасляной кислоты и их фармацевтически приемлемых производных при лечении никотиновой зависимости
IL147876A IL147876A (en) 1999-07-30 2002-01-28 Use of agonists of gabab receptors or pharmaceutically acceptable derivatives thereof for the preparation of pharmaceutical compositions for reducing the wish of smoking in nicotine-dependent patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI001715A IT1313585B1 (it) 1999-07-30 1999-07-30 Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.

Publications (3)

Publication Number Publication Date
ITMI991715A0 ITMI991715A0 (it) 1999-07-30
ITMI991715A1 ITMI991715A1 (it) 2001-01-30
IT1313585B1 true IT1313585B1 (it) 2002-09-09

Family

ID=11383467

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999MI001715A IT1313585B1 (it) 1999-07-30 1999-07-30 Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.

Country Status (16)

Country Link
EP (1) EP1202727B1 (enExample)
CN (1) CN1176650C (enExample)
AT (1) ATE285763T1 (enExample)
AU (1) AU6153400A (enExample)
CA (1) CA2379752C (enExample)
DE (1) DE60017147T2 (enExample)
DK (1) DK1202727T3 (enExample)
ES (1) ES2235913T3 (enExample)
HK (1) HK1046849B (enExample)
IL (2) IL147876A0 (enExample)
IT (1) IT1313585B1 (enExample)
PL (1) PL196334B1 (enExample)
PT (1) PT1202727E (enExample)
RU (1) RU2262352C2 (enExample)
SI (1) SI1202727T1 (enExample)
WO (1) WO2001008675A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019163A2 (en) * 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JP4498407B2 (ja) 2006-12-22 2010-07-07 キヤノン株式会社 プロセスカートリッジ、電子写真画像形成装置、及び、電子写真感光体ドラムユニット
JP5291123B2 (ja) 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
JP2012519212A (ja) 2009-03-03 2012-08-23 ゼノポート，インコーポレイティド Ｒ−バクロフェンプロドラッグの持効性放出経口投与形
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
WO2011081558A1 (ru) * 2009-08-21 2011-07-07 Komissarov Jury Vladimirovich Курительное устройство для отказа от табачного курения
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
WO2019195813A1 (en) * 2018-04-06 2019-10-10 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5073539A (en) * 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
RU2132203C1 (ru) * 1998-09-03 1999-06-27 Шакирзянов Галимзян Закирович Способ лечения табачной зависимости и антитабачный комбинированный препарат

Also Published As

Publication number Publication date
SI1202727T1 (enExample) 2005-08-31
CA2379752C (en) 2008-05-27
DE60017147T2 (de) 2006-01-12
CN1377265A (zh) 2002-10-30
PT1202727E (pt) 2005-05-31
DK1202727T3 (da) 2005-05-09
EP1202727A1 (en) 2002-05-08
ATE285763T1 (de) 2005-01-15
ITMI991715A0 (it) 1999-07-30
HK1046849B (en) 2005-07-15
IL147876A0 (en) 2002-08-14
RU2262352C2 (ru) 2005-10-20
DE60017147D1 (de) 2005-02-03
CN1176650C (zh) 2004-11-24
HK1046849A1 (en) 2003-01-30
EP1202727B1 (en) 2004-12-29
ITMI991715A1 (it) 2001-01-30
PL353373A1 (en) 2003-11-17
AU6153400A (en) 2001-02-19
WO2001008675A1 (en) 2001-02-08
CA2379752A1 (en) 2001-02-08
IL147876A (en) 2007-06-17
PL196334B1 (pl) 2007-12-31
ES2235913T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
IT1313585B1 (it) Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
EP1027011A4 (en) ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING
SE8804629D0 (sv) New therapeutically active compounds
HU9402003D0 (en) Composition to help stop smoking
NO20083842L (no) Anvendelse av opploselig lymfotoksin-beta-reseptor for fremstilling av medikamenter
MY130619A (en) Pharmaceutical formulations of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
MY119181A (en) Aryl pyrimidine derivatives
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
YU46496A (sh) Upotreba 4-hlor-5-(imidazolin-2-il(amino)-6-metoksi-2-metilpirimidina
DK1187611T3 (da) Oftalmiske histaminholdige sammensætninger og anvendelse deraf
SE9402880D0 (sv) New peptide derivatives
PT1052973E (pt) Formulacoes transmucosais de levosimendano
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
AU2204701A (en) Formulations of adenosine a1 agonists
EA200300271A1 (ru) Соединения для лечения расстройств, связанных с зависимостью
PT1085907E (pt) Solucao compreendendo prostaglandinas e alcool benzilico
AU2203101A (en) Formulations of adenosine a1 agonists
ITRM910155A0 (it) Preparati farmaceutici per la terapia dei tumori contenenti colchicina come principio attivo e metodi per l'impiego degli stessi.
BR0015310A (pt) Uso de agonistas do receptor de dopamina d3
SE9802555D0 (sv) New pharmaceutical preparation and method
ITTO950126A0 (it) Nuovi derivati poliammidici dell'ornitina, della lisina ed analoghi ad attivita' cck-b e gastrina, procedimento per la loro preparazione e loro uso farmaceutico
MXPA02001308A (es) Derivados de pirido (1, 2-a)bencimidazol sustituidos en el anillo c-6 utiles en el tratamiento de trastornos del sistema nervioso central.
IT8709512A0 (it) Sedia per l'uso dei servizi igienici da parte di invalidi